Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants-Reference-Cited by-同舟云学术

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants

Published:2022-10-06 Issue:14 Volume:387 Page:1329-1331
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Qu Panke¹,Faraone Julia N.¹,Evans John P.¹^ORCID,Zheng Yi-Min¹,Yu Lianbo¹,Ma Qin¹^ORCID,Carlin Claire¹,Lozanski Gerard¹,Saif Linda J.¹,Oltz Eugene M.¹,Gumina Richard J.¹,Liu Shan-Lu¹^ORCID

Affiliation:

1. Ohio State University, Columbus, Ohio

Funder

National Cancer Institute

National Institutes of Health

Glenn Barber Fellowship

Robert J. Anthony Fund for Cardiovascular Research

JB Cardiovascular Research Fund

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2210546

Reference5 articles.

1. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

2. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

3. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

4. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

5. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2;Journal of Infection and Chemotherapy;2024-10

2. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023;Eurosurveillance;2024-09-12

3. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective;Nature Communications;2024-07-03

4. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial;The Lancet Microbe;2024-06

5. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges;npj Vaccines;2024-05-23